keyword
https://read.qxmd.com/read/37577786/fixed-combination-halobetasol-propionate-and-tazarotene-topical-lotion-decreases-tnf-%C3%AE-and-il-17a-levels-in-psoriatic-lesions
#21
JOURNAL ARTICLE
Zoe Diana Draelos, Matthew M Draelos, Tina Lin, Abby Jacobson
OBJECTIVE: Fixed-combination halobetasol propionate (0.01%) and tazarotene (0.045%) lotion (HP/TAZ) is approved for the treatment of plaque psoriasis in adults, with a demonstrated efficacy and safety profile in phase 3 trials. This study examined the effect of HP/TAZ on the reduction of tumor necrosis factor alpha (TNF-α) and interleukin 17 A (IL-17A) and its correlation to psoriasis improvement. MATERIALS AND METHODS: Ten adults with mild-to-moderate plaque psoriasis and 2 symmetrical plaques self-applied HP/TAZ (treated plaque) or vehicle lotion (untreated plaque) for 12 weeks...
December 2023: Journal of Dermatological Treatment
https://read.qxmd.com/read/37396622/tackling-acne-vulgaris-by-fabrication-of-tazarotene-loaded-essential-oil-based-microemulsion-in-vitro-and-in-vivo-evaluation
#22
JOURNAL ARTICLE
Noha M Badawi, Rania M Yehia, Caroline Lamie, Khaled A Abdelrahman, Dalia A Attia, Doaa A Helal
This study aimed to formulate and optimize an anti-acne drug namely tazarotene (TZR) in essential oil-based microemulsion (ME) using either Jasmine oil (Jas) or Jojoba oil (Joj). TZR-MEs were prepared using two experimental designs (Simplex Lattice Design®) and characterized for droplet size, polydispersity index, and viscosity. Further in vitro , ex vivo, and in vivo investigations were performed for the selected formulations. Results revealed that TZR-selected MEs exhibited suitable droplet size, homogenous dispersions, and acceptable viscosity, in addition to spherical-shaped particles in morphology...
December 2023: International journal of pharmaceutics: X
https://read.qxmd.com/read/37247911/tig1-inhibits-the-mtor-signaling-pathway-in-malignant-melanoma-through-the-vac14-protein
#23
JOURNAL ARTICLE
Chun-Hua Wang, Lu-Kai Wang, Chang-Chieh Wu, Mao-Liang Chen, Chan-Yen Kuo, Rong-Yaun Shyu, Fu-Ming Tsai
BACKGROUND/AIM: Currently, there are few drug options available to treat malignant melanoma. Tazarotene-inducible gene 1 (TIG1) was originally isolated from skin tissue, but its function in skin tissue has not been clarified. The aim of this study was to elucidate the effect of TIG1 and mTOR signaling pathways associated with VAC14 on melanoma. MATERIALS AND METHODS: The expression of TIG1 and VAC14 in melanoma tissue was analyzed using a melanoma tissue cDNA array...
June 2023: Anticancer Research
https://read.qxmd.com/read/37063830/phospholipase-a-and-acyltransferase-4-retinoic-acid-receptor-responder-3-at-the-intersection-of-tumor-suppression-and-pathogen-restriction
#24
REVIEW
Jian-Yong Zhao, Xiang-Kun Yuan, Rui-Zhen Luo, Li-Xin Wang, Wei Gu, Daisuke Yamane, Hui Feng
Phospholipase A and acyltransferase (PLAAT) 4 is a class II tumor suppressor with phospholipid metabolizing abilities. It was characterized in late 2000s, and has since been referred to as 'tazarotene-induced gene 3' (TIG3) or 'retinoic acid receptor responder 3' (RARRES3) as a key downstream effector of retinoic acid signaling. Two decades of research have revealed the complexity of its function and regulatory roles in suppressing tumorigenesis. However, more recent findings have also identified PLAAT4 as a key anti-microbial effector enzyme acting downstream of interferon regulatory factor 1 (IRF1) and interferons (IFNs), favoring protection from virus and parasite infections...
2023: Frontiers in Immunology
https://read.qxmd.com/read/36950046/challenges-in-psoriatic-disease-addressed-by-fixed-combination-halobetasol-propionate-0-01-and-tazarotene-0-045-lotion
#25
REVIEW
Leon Kircik, Emil A Tanghetti, Adam Friedman, Kristine Kucera, Abby Jacobson
OBJECTIVE: The fixed-dose corticosteroid/retinoid combination halobetasol propionate (0.01%) and tazarotene (0.045%) lotion (HP/TAZ) is approved for topical treatment of plaque psoriasis in adults. In addition to its current indication for plaque psoriasis, a growing body of clinical data suggests that HP/TAZ may be a beneficial therapy for palmoplantar and scalp psoriasis. Here, we discuss the efficacy and safety of HP/TAZ in various psoriatic phenotypes and related conditions. METHODS: Three studies (one post-hoc analysis, two open-label reports) of HP/TAZ were identified for this discussion...
March 2023: Journal of Clinical and Aesthetic Dermatology
https://read.qxmd.com/read/36877884/breaking-the-frustrating-cycle-of-topical-steroids-in-psoriasis-a-review-of-a-novel-vehicle-for-fixed-dose-combination-halobetasol-propionate-tazarotene
#26
JOURNAL ARTICLE
Leon Kircik, Neal Bhatia, Edward Lain, Abby Jacobson
Topical therapies are commonly used to treat psoriasis, either as monotherapy for milder disease or as adjuncts to systemic and biologic drugs. Topical steroids and tazarotene are both options for topical psoriasis treatment, but as monotherapies, they are associated with adverse events (AEs) that make adherence to prescribed treatment challenging. In addition, the topical vehicles may have an unappealing appearance or texture that proves impractical for patients. Consequently, patients may not use treatments as prescribed...
March 1, 2023: Journal of Drugs in Dermatology: JDD
https://read.qxmd.com/read/36789546/drug-screening-identifies-tazarotene-and-bexarotene-as-therapeutic-agents-in-multiple-sulfatase-deficiency
#27
JOURNAL ARTICLE
Lars Schlotawa, Karolina Tyka, Matthias Kettwig, Rebecca C Ahrens-Nicklas, Matthias Baud, Tea Berulava, Nicola Brunetti-Pierri, Alyssa Gagne, Zackary M Herbst, Jean A Maguire, Jlenia Monfregula, Tonatiuh Pena, Karthikeyan Radhakrishnan, Sophie Schröder, Elisa A Waxman, Andrea Ballabio, Thomas Dierks, André Fischer, Deborah L French, Michael H Gelb, Jutta Gärtner
Multiple sulfatase deficiency (MSD, MIM #272200) results from pathogenic variants in the SUMF1 gene that impair proper function of the formylglycine-generating enzyme (FGE). FGE is essential for the posttranslational activation of cellular sulfatases. MSD patients display reduced or absent sulfatase activities and, as a result, clinical signs of single sulfatase disorders in a unique combination. Up to date therapeutic options for MSD are limited and mostly palliative. We performed a screen of FDA-approved drugs using immortalized MSD patient fibroblasts...
February 15, 2023: EMBO Molecular Medicine
https://read.qxmd.com/read/36745378/meeting-patient-expectations-of-topical-psoriasis-treatment-evidence-supporting-the-use-of-fixed-combination-halobetasol-tazarotene-lotion
#28
JOURNAL ARTICLE
James Del Rosso, George Han, April Armstrong, G Michael Lewitt, Abby Jacobson
Discordance between patient and clinician treatment goals and expectations can present a challenge to implementation of effective therapeutic plans. Because topical treatments are commonly used for plaque psoriasis, both as monotherapy and adjuncts to other treatment modalities, providers need to understand the concerns of patients with psoriasis regarding use of topical products. Psoriasis is a complex and chronic disease with treatment needs that may change over time, influencing patient treatment goals and expectations of efficacy...
February 1, 2023: Journal of Drugs in Dermatology: JDD
https://read.qxmd.com/read/36745373/an-investigator-initiated-trial-of-a-polymeric-emulsion-of-halobetasol-propionate-and-tazarotene-in-the-treatment-of-palmoplantar-psoriasis
#29
JOURNAL ARTICLE
Jenna Yousif, Folawiyo Babalola, Caroline Campbell, Alice Gottlieb, Jessica Vargas, Krystal Mitchell
UNLABELLED: Copy: Palmoplantar psoriasis is a chronic, difficult-to-treat localized variant of psoriasis that affects the palms and soles, significantly affecting patient's quality of life. OBJECTIVE: To evaluate the synergistic effect of a fixed-combination topical lotion composed of halobetasol propionate 0.01% and tazarotene 0.045% in the treatment of palmoplantar psoriasis. METHODS: This was an open-label investigator-initiated trial involving 21 patients with moderate-to-severe palmoplantar plaque-type psoriasis who underwent treatment with halobetasol propionate 0...
February 1, 2023: Journal of Drugs in Dermatology: JDD
https://read.qxmd.com/read/36651791/topical-roflumilast-zoryve-for-plaque-psoriasis
#30
JOURNAL ARTICLE
(no author information available yet)
No abstract text is available yet for this article.
January 23, 2023: Medical Letter on Drugs and Therapeutics
https://read.qxmd.com/read/36630478/novel-synergistic-approach-tazarotene-calcipotriol-loaded-pva-pvp-nanofibers-incorporated-in-hydrogel-film-for-management-and-treatment-of-psoriasis
#31
JOURNAL ARTICLE
Sunita Thakur, Md Meraj Anjum, Shweta Jaiswal, Anand Kumar, Payal Deepak, Sneha Anand, Sanjay Singh, Paruvathanahalli Siddalingam Rajinikanth
Psoriasis is an autoimmune skin disease that generally affects 1%-3% of the total population globally. Effective treatment of psoriasis is limited because of numerous factors, such as ineffective drug delivery and efficacy following conventional pharmaceutical treatments. Nanofibers are widely being used as nanocarriers for effective treatment because of their multifunctional and distinctive properties, including a greater surface area, higher volume ratio, increased elasticity and improved stiffness and resistance to traction, favorable biodegradability, high permeability, and sufficient oxygen supply, which help maintain the moisture content of the skin and improve the bioavailability of the drugs...
February 6, 2023: Molecular Pharmaceutics
https://read.qxmd.com/read/36622889/low-irritation-potential-of-tazarotene-0-045-lotion-head-to-head-comparison-to-adapalene-0-3-gel-and-trifarotene-0-005-cream-in-two-studies
#32
RANDOMIZED CONTROLLED TRIAL
Zoe D Draelos
BACKGROUND: Irritation with topical retinoids presents a significant impediment to acne treatment adherence. Two studies assessed the irritation potential of tazarotene 0.045% lotion versus adapalene 0.3% gel and trifarotene 0.005% cream. METHODS: In two double-blind, 12-day modified cumulative irritation patch studies, healthy adults (N = 20 each) had two active patches, containing 0.1 cc of tazarotene 0.045% lotion and either adapalene 0.3% gel (Study 1) or trifarotene 0...
December 2023: Journal of Dermatological Treatment
https://read.qxmd.com/read/36607764/supplement-individual-article-a-reappraisal-of-fixed-combination-halobetasol-propionate-and-tazarotene-for-the-treatment-of-psoriasis-biological-underpinnings-therapeutic-mechanisms-and-economic-considerations
#33
JOURNAL ARTICLE
Naiem Issa, Leon Kircik
Psoriasis is a complex inflammatory disease, which can be triggered by the interplay among keratinocytes, various immune cells, and even dermal vascular endothelial cells. Understanding of the key players and cytokine/chemokine messengers involved in the initiation and maintenance of psoriasis has significantly evolved and led to numerous systemic biologic therapies targeting those specific components. These therapies, despite their successes, do not ubiquitously affect all pathogenic cellular pathways. They also carry their risks and may be contraindicated in certain patient populations...
January 1, 2023: Journal of Drugs in Dermatology: JDD
https://read.qxmd.com/read/36468963/supplement-individual-articles-update-on-truncal-acne-a-review-of-treatments-for-a-neglected-disease-and-the-re-emergence-of-tazarotene
#34
REVIEW
Naiem Issa, Zoe Draelos, Emil Tanghetti, Leon Kircik
Acne vulgaris of the trunk carries with it a major psychosocial impact and an unmet need for adequate management. Approximately 50% of patients with facial acne also exhibit involvement of the back, chest, and/or upper arms. The trunk poses a therapeutic challenge given its occlusion by clothing, the tendency for mechanical rubbing, a sebum physiology that differs from the face, as well as the fact that there is a large surface area for topical therapies to cover. Furthermore, truncal acne is underreported for a variety of reasons such as cultural barriers, sentiments of embarrassment, and prioritization of facial acne...
December 1, 2022: Journal of Drugs in Dermatology: JDD
https://read.qxmd.com/read/36382987/improvements-in-acne-and-skin-oiliness-with-tazarotene-0-045-lotion-in-patients-with-oily-skin
#35
JOURNAL ARTICLE
Emil A Tanghetti, Joshua A Zeichner, Michael Gold, Neil Sadick, Fran E Cook-Bolden, Leon H Kircik, Linda Stein Gold, Jonathan Weiss, Stephen K Tyring, James Q Del Rosso, Eric Guenin
BACKGROUND: Excessive sebum production is a factor in acne development. Tazarotene 0.045% lotion has demonstrated reductions in acne lesions and acne-induced sequalae. OBJECTIVE: Evaluate efficacy, changes in skin oiliness, and safety with tazarotene 0.045% lotion in participants with moderate-to-severe acne and oily skin. METHODS: In two phase 3, double-blind, 12-week studies (NCT03168321; NCT03168334), participants aged ≥9 years with moderate-to-severe acne were randomized 1:1 to once-daily tazarotene 0...
November 16, 2022: Journal of Dermatological Treatment
https://read.qxmd.com/read/36319021/management-of-nail-disease-in-patients-with-psoriatic-arthritis-an-updated-literature-review-informing-the-2021-grappa-treatment-recommendations
#36
JOURNAL ARTICLE
Dhruvkumar Laheru, Anna Antony, Sueli Carneiro, Vito Di Lernia, Amit Garg, Thorvardur Jon Love, Karla Del Rocio Macias Garcia, José Alexandre Mendonça, Sandeep Mukherjee, Rodica Olteanu, Lourdes Perez-Chada, Cheryl F Rosen, Rachel Tannenbaum, Michel Alexandre Yazbek
OBJECTIVE: Nail psoriasis is common, impairs fine motor finger functioning, affects cosmesis, and is associated with a lower quality of life. This review updates the previous Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) treatment recommendations for nail psoriasis. METHODS: This systematic literature review of the PubMed, MEDLINE, Embase, and Cochrane databases examined the updated evidence since the last GRAPPA nail psoriasis treatment recommendations published in 2014...
March 2023: Journal of Rheumatology
https://read.qxmd.com/read/36301760/novel-and-emerging-treatment-options-for-acne-vulgaris
#37
REVIEW
Nicole Auffret, Jean Paul Claudel, Marie-Thérèse Leccia, Fabienne Ballanger, Brigitte Dreno
The principal actors in acne are the sebaceous gland, keratinocytes of the follicle and skin microbiome/innate immunity. Current acne treatments are frequently accompanied by side effects or may cause antibacterial resistance. New formulations and emerging treatments with novel mechanisms of action and improved formulations have recently been made available or are currently under development. This review provides an update on the most recent advances in topical or systemic acne therapy related to recent data on the pathophysiology of acne...
July 1, 2022: European Journal of Dermatology: EJD
https://read.qxmd.com/read/36223060/matching-adjusted-indirect-comparison-of-long-term-efficacy-and-safety-outcomes-for-calcipotriol-plus-betamethasone-dipropionate-foam-versus-halobetasol-proprionate-plus-tazarotene-lotion-in-the-treatment-of-plaque-psoriasis
#38
JOURNAL ARTICLE
David N Adam, Marie Y Jablonski Bernasconi, Henrik Thoning, Jashin J Wu
INTRODUCTION: To date, there have been no head-to-head clinical studies comparing calcipotriol 0.005% plus betamethasone dipropionate 0.064% (Cal/BD) aerosol foam and halobetasol propionate 0.01% plus tazarotene 0.045% (HP/Taz) lotion for the treatment of plaque psoriasis. However, the efficacy of 4 weeks of Cal/BD foam and 8 weeks of HP/Taz lotion has been compared using a matching-adjusted indirect comparison (MAIC) approach. Here, we compare the efficacy and safety of Cal/BD foam and HP/Taz lotion for up to 52 weeks...
October 12, 2022: Dermatology and Therapy
https://read.qxmd.com/read/36220974/use-of-retinoids-in-topical-antiaging-treatments-a-focused-review-of-clinical-evidence-for-conventional-and-nanoformulations
#39
REVIEW
Daniela Milosheska, Robert Roškar
Nowadays, numerous skincare routines are used to rejuvenate aging skin. Retinoids are one of the most popular ingredients used in antiaging treatments. Among the representatives of retinoids, tretinoin is considered the most effective agent with proven antiaging effects on the skin and can be found in formulations approved as medicines for topical treatment of acne, facial wrinkles, and hyperpigmentation. Other retinoids present in topical medicines are used for various indications, but only tazarotene is also approved as adjunctive agent for treatment of facial fine wrinkling and pigmentation...
December 2022: Advances in Therapy
https://read.qxmd.com/read/36219602/management-of-psoriasis-with-topicals-applying-the-2020-aad-npf-guidelines-of-care-to-clinical-practice
#40
REVIEW
Vipawee S Chat, Donovan G Kearns, Shelley K Uppal, George Han, Jashin J Wu
Topical medications have high utility in the treatment of psoriasis because of their localized effect and ability to be used as both monotherapy and adjunctive therapy. The American Academy of Dermatology (AAD) and the National Psoriasis Foundation (NPF) published guidelines in 2020 regarding the management of psoriasis with topical therapies. These guidelines are a framework that assist clinicians treating psoriasis patients with topical agents including steroids, calcineurin inhibitors (CNIs), vitamin D analogues, retinoids (tazarotene), emollients, keratolytics (salicylic acid), anthracenes (anthralin), and keratoplastics (coal tar)...
August 2022: Cutis; Cutaneous Medicine for the Practitioner
keyword
keyword
36379
2
3
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.